Identification of loss-of-function *AQP2* mutations responsible for autosomal-recessive or autosomal-dominant nephrogenic diabetes insipidus
============================================================================================================================================

Complex polyuric cases as described in the abstract are included in \[[@bib1]--[@bib6]\] and the benefit of genomic information in \[[@bib7]\].

On the basis of 1-desamino-8-D-arginine vasopressin (dDAVP) infusion studies and measurements of plasma cyclic adenosine monophosphate (cAMP) levels following pharmacological intravenous doses of dDAVP, a vasopressin V2 synthetic analog, we first suggested that X-linked nephrogenic diabetes insipidus (NDI) was a pre-cyclic AMP defect \[[@bib8], [@bib9]\]. Male patients with X-linked NDI did not stimulate their coagulation factor release or plasma cyclic AMP level after a pharmacological infusion of dDAVP, a suggestion of a loss of function of both renal and extrarenal vasopressin V2 receptors. As in many other X-linked diseases, males are severely affected with polyuria and polydipsia, by contrast, women are rarely symptomatic (for a discussion on symptomatic heterozygous female patients bearing *AVPR2* mutations see: \[[@bib10]\]). Subsequent haplotype analysis of X-linked NDI in ancestrally independent families followed by my laboratory revealed that all affected male subjects were segregated with X-q28 markers where the vasopressin receptor gene is localized \[[@bib11]\]. At the same time, Birnbaumer \[[@bib12]\] and her team cloned the vasopressin V2 receptor by expression, the readout signal was again stimulation of cAMP from transfected cells, and, in collaboration with her, we rapidly demonstrated that a frameshift mutation in the *AVPR2* gene, the gene coding for the vasopressin V2 receptor, was responsible for X-linked NDI \[[@bib13]\].

Using dDAVP infusion studies and other families with severe polyuric characteristics in both male and female individuals, a non-X-linked form of NDI with a post-receptor (post-cAMP) defect was suggested \[[@bib14]--[@bib16]\]. A patient who presented shortly after birth with typical features of NDI but who exhibited normal coagulation and normal fibrinolytic and vasodilatory responses to dDAVP was shown to be a compound heterozygote for two missense mutations (R187C and S217P) in the *AQP2* gene \[[@bib17]\]. Expression of each of these two mutations in Xenopus oocytes revealed non-functional water channels. The oocytes of the African clawed frog Xenopus have provided a most useful test bed for looking at the functioning of many channel proteins. (See recent characterization of proteins with gain of function responsible for autosomal-dominant pseudohypoaldosteronism type II \[[@bib18]\].) Oocytes are large cells about to become mature eggs ready for fertilization. They have all the normal translation machinery of living cells, so they will respond to the injection of messenger RNA by making the encoded protein \[[@bib19]\]. This convenient expression system was key to the discovery of AQP1 by Agre \[[@bib20]\] because frog oocytes have very low permeability and survive even in freshwater ponds. A representation of the injection process and expression of two *AQP2* naturally occurring mutants responsible for autosomal-recessive NDI are described in [Figure 1a](#fig1){ref-type="fig"}. When subjected to a 20-mOsm osmotic shock, control oocytes have exceedingly low water permeability but test oocytes become highly permeable to water. These osmotic water permeability assays demonstrated an absence or very low water transport of the complementary RNA with *AQP2* mutations ([Figure 1b](#fig1){ref-type="fig"}). Immunofluorescence and immunoblot studies demonstrated that these recessive mutants were retained in the endoplasmic reticulum \[[@bib21], [@bib22]\].

![(**a**) Immunofluorescence of *AQP2* expressed in oocytes. Oocytes were not injected (1 control) or injected with either AQP2-wt (2, 1 ng), AQP2-D150E (3, 10 ng) or AQP2-G196D (4, 10 ng) messenger RNAs and incubated for 3 days prior to assay. Oocytes were immunostained and visualized with antibodies to AQP2. The injection process is represented in the right of the figure \[[@bib21]\]. (**b**) Determination of water permeabilities (Pf) of wild-type (WT) AQP2 and mutants expressed in Xenopus oocytes. Oocytes were injected with either AQP2-wt (1 ng), AQP2-D150E (10 ng) or AQP2-G196D (10 ng) messenger RNAs and incubated for 2 days prior to assay. Determination of water permeabilities was performed by evaluation of volume increase in oocytes as induced by a 20-mosmol/kg H2O hypotonic shock \[[@bib21]\].](ndtplussfs029f01_4c){#fig1}

Of interest, in the first identification of *AQP2* mutants by the Nijmegen group \[[@bib17]\], the sequencing of the *AQP2* gene in this isolated patient with autosomal-recessive diabetes insipidus followed a candidate gene approach guided by new understanding of the necessity, after vasopressin recognition and signaling, to insert water channels in the luminal membrane of principal cells of the collecting ducts to achieve water reabsorption \[[@bib23]\]. We used the new sequencing data provided by Deen *et al.* to solve the molecular identification of NDI in two inbred Pakistani girls with non-X-linked NDI originally reported by Langley *et al.* \[[@bib16]\]. They were found to be homozygous for the *AQP2* V71M mutation, a recurrent mutation in Pakistani kindred since two other children from two other Pakistani families living in the UK, said to be unrelated, were found to bear the same mutation on the same *AQP2* haplotype ([Figure 2](#fig2){ref-type="fig"}).

![Pedigree of three Pakistani families referred to our laboratory each bearing the V71M AQP2 mutation (M). Family Aqp1 was first described by Langley \[[@bib16]\]. Squares and circles represent male and female subjects, respectively, with unaffected individuals (open symbols), carriers (half-filled symbols) and affected individuals (solid symbol); n indicates normal allele. Haplotypes consist of markers that flank the AQP2 gene and that have been described previously \[[@bib24]\]. The alleles bearing the individual mutations are identical suggesting a common ancestry.](ndtplussfs029f02_ht){#fig2}

To date, 46 putative disease-causing *AQP2* mutations have been identified in 52 NDI families ([Table 1](#tbl1){ref-type="table"} and [Figure 3](#fig3){ref-type="fig"}). *AQP2* mutations in autosomal-recessive NDI, which are located throughout the gene, result in misfolded proteins that are retained in the endoplasmic reticulum ([Table 1](#tbl1){ref-type="table"}; [Figure 3](#fig3){ref-type="fig"}). In contrast, the dominant mutations reported to date are located in the region that codes for the carboxyl terminus of *AQP2* \[[@bib55]\]. Dominant AQP2 mutants form heterotetramers with wt-AQP2 and are misrouted \[[@bib28], [@bib36], [@bib40], [@bib45]--[@bib48], [@bib51]--[@bib54]\]. Patients bearing these dominant mutations have a less severe phenotype as compared to patients who are compound heterozygotes or homozygotes for recessive mutations: the patient and her daughter first described to bear the AQP2-E258K-dominant mutation increased their urine osmolality to 350 mOsm/kg H~2~O following dDAVP \[[@bib45]\]. Also the patient with a detailed phenotype described by Robertson and Koop \[[@bib25]\] increased her urine osmolality to 220 mOsm/kg H~2~O during a mildly hypertonic dehydration, to 258 mOsm/kg H~2~O after dDAVP and to 305 mOsm/kg H~2~O after hydrochlorothiazide and indomethacin. This patient was found to be heterozygous for the R254Q mutation, possibly interfering with the S256 phosphorylation site \[[@bib40]\]. In the mutant AQP2 (763--772) knockin mice, Sohara *et al.* \[[@bib56]\] demonstrated a slight increase in urine osmolality following dehydration but a marked increase after the administration of Rolipram, a phosphodiesterase-4 inhibitor.

###### 

Listing of 46 putative disease-causing AQP2 mutations

  Count   No. of families   Name of mutation                                                                                                               Domain   Nucleotide change   Predicted consequence   Reference
  ------- ----------------- ------------------------------------------------------------------------------------------------------------------------------ -------- ------------------- ----------------------- ------------------------------------------------------------------------------------------------------------------------------------
                            Missense \[[@bib25]\]                                                                                                                                                               
  1       1                 M1I                                                                                                                            NH2      ATG-to-ATT          Met-to-Ile              Sahakitrungruang *et al.* \[[@bib26]\]
  2       1                 L22V                                                                                                                           TMI      CTC-to-GTC          Leu-to-Val              Canfield *et al.* \[[@bib27]\]
  3       1                 V24A                                                                                                                           TMI                          Val-to-Ala              Leduc-Nadeau *et al.* \[[@bib22]\]
  4       1                 L28P                                                                                                                           TMI      CTC-to-CCC          Leu-to-Pro              Marr *et al.* \[[@bib28]\]
  5       1                 G29S                                                                                                                           TM1                          Gly-to-Ser              Sahakitrungruang *et al.* \[[@bib26]\]
  6       2                 A47V                                                                                                                           TMII     GCG-to-GTG          Ala-to-Val              Marr *et al.* \[[@bib28]\]; Muller *et al.* \[[@bib29]\]
  7       2                 Q57P                                                                                                                           TMII     CAG-to-CCG          Glu-to-Pro              Lin *et al.* \[[@bib24]\]
  8       1                 G64R                                                                                                                           CII      GGG-to-AGG          Gly-to-Arg              van Lieburg *et al.* \[[@bib30]\]
  9       1                 N68S                                                                                                                           CII      AAC-to-AGC          Asn-to-Ser              Mulders *et al.* \[[@bib31]\]
  10      1                 A70D                                                                                                                           CII      GCC-to-GAC          Ala-to-Asp              Cheong *et al.* \[[@bib32]\]
  11      2                 V71M                                                                                                                           CII      GTG-to-ATG          Val-to-Met              Marr *et al.* \[[@bib28]\]
  12      2                 G100V                                                                                                                          TMIII    GGA-to-GTA          Gly-to-Val              Lin *et al.* \[[@bib24]\]
  13      1                 G100R                                                                                                                          TMIII    GGA-to-AGA          Gly-to-Arg              Carroll *et al.* \[[@bib33]\]
  14      1                 I107D                                                                                                                          EII      ATC-to-AAC          Ile-to-Asp              Zaki *et al.* \[[@bib34]\]
  15      1                 T125M                                                                                                                          EII      ACG-to-ATG          Thr-to-Met              Goji *et al.* \[[@bib35]\]; Kuwahara \[[@bib36]\] (same family)
  16      1                 T126M                                                                                                                          EII      ACG-to-ATG          Thr-to-Met              Mulders *et al.* \[[@bib31]\]
  17      1                 A147T                                                                                                                          TMIV     GCC-to-ACC          Ala-to-Thr              Mulders *et al.* \[[@bib31]\]
  18      2                 D150E                                                                                                                          ICII     GAT-to-GAA          Asp-to-Glu              Guyon *et al.* \[[@bib21]\]; Iolascon *et al.* \[[@bib37]\]
  19      1                 V168M                                                                                                                          TMV      GTG-to-ATG          Val-to-Met              Vargas-Poussou *et al.* \[[@bib38]\]
  20      1                 G175R                                                                                                                          TMV      GGG-to-AGG          Gly-to-Arg              Goji *et al.* \[[@bib35]\]; Kuwahara \[[@bib36]\] (same family); Boccalandro *et al.* \[[@bib39]\]
  21      1                 G180S                                                                                                                          EIII     GGC-to-AGC          Gly-to-Ser              Carroll *et al.* \[[@bib33]\]
  22      1                 C181W                                                                                                                          EIII     TGC-to-TGG          Cys-to-Trp              Canfield *et al.* \[[@bib27]\]
  23      1                 P185A                                                                                                                          EIII     CCT-to-GCT          Pro-to-Ala              Marr *et al.* \[[@bib28]\]
  24      3                 R187C                                                                                                                          EIII     CGC-to-TGC          Arg-to-Cys              Deen *et al.* \[[@bib17]\]; van Lieburg *et al.* \[[@bib30]\]; de Mattia *et al.* \[[@bib40]\]; Leduc-Nadeau *et al.* \[[@bib22]\]
  25      1                 R187H                                                                                                                          EIII     CGC-to-CAC          Arg-to-His              Cheong 2005 \#1846 \[[@bib32]\]
  26      1                 A190T                                                                                                                          EIII     GCT-to-ACT          Ala-to-Thr              Kuwahara \[[@bib36]\]; de Mattia *et al.* \[[@bib40]\]
  27      1                 G196D                                                                                                                          EIII     GGC-to-GAC          Gly-to-Asp              Guyon *et al.* \[[@bib21]\]
  28      1                 W202C                                                                                                                          EIII     TGG-to-TGT          Trp-to-Cys              Oksche *et al.* \[[@bib41]\]
  29      1                 G215C                                                                                                                          TMVI     GGC-to-TGC          Gly-to-Cys              Iolascon *et al.* \[[@bib37]\]
  30      2                 S216P                                                                                                                          TMVI     TCC-to-CCC          Ser-to-Pro              Deen *et al.* \[[@bib17]\]; Vargas-Poussou *et al.* \[[@bib38]\]
  31      1                 S216F                                                                                                                          TMVI     TCC-to-TTC          Ser-to-Phe              Moon *et al.* \[[@bib42]\]
  32      1                 K228E                                                                                                                          CIV                          Lys-to-Glu              Leduc-Nadeau *et al.* \[[@bib22]\]
  33      1                 R254Q                                                                                                                          CIV      CGG-to-CAG          Arg-to-Gln              Robertson *et al.* \[[@bib25]\]; Savelkoul *et al.* \[[@bib43]\]
  34      1                 R254L                                                                                                                          CIV      CGG-to-CTG          Arg-to-Leu              de Mattia *et al.* \[[@bib40]\]; de Mattia *et al.* \[[@bib44]\]
  35      1                 E258K                                                                                                                          CIV      GAG-to-AAG          Glu-to-Lys              Mulders *et al.* \[[@bib45]\]; Kamsteeg *et al.* \[[@bib46]\]; Kamsteeg *et al.* \[[@bib47]\]; Kamsteeg *et al.* \[[@bib48]\]
  36      2                 P262L                                                                                                                          CIV      CCG-to-CTG          Pro-to-Leu              Kuwahara \[[@bib36]\]; de Mattia *et al.* \[[@bib40]\]
                            Nonsense \[[@bib2]\]                                                                                                                                                                
  1       2                 R85X                                                                                                                           CII      CGA-to-TGA          Arg-to-stop             Vargas-Poussou *et al.* \[[@bib38]\]; Bircan *et al.* \[[@bib49]\]
  2       1                 G100X                                                                                                                          TMIII    GGA-to-TGA          Gly-to-stop             Hochberg *et al.* \[[@bib50]\]
                            Frameshift \[[@bib6]\]                                                                                                                                                              
  1       1                 369delC                                                                                                                        EII      1bp deletion        Stop at Codon 131       van Lieburg *et al.* \[[@bib30]\]
  2       1                 721delG                                                                                                                        CIV      1 bp deletion       Post-elongation         Kuwahara *et al.* \[[@bib51]\]; Ohzeki *et al.* \[[@bib52]\]
  3       1                 727delG                                                                                                                        CIV      1 bp deletion       Post-elongation         Marr *et al.* \[[@bib53]\]
  4       1                 763-772del                                                                                                                     CIV      10 bp deletion      Post-elongation         Kuwahara *et al.* \[[@bib51]\]
  5       1                 779--780insA                                                                                                                   CIV      1 bp insertion      Post-elongation         Kamsteeg *et al.* \[[@bib54]\]
  6\.     1                 812-818del                                                                                                                     CIV      7 bp deletion       Post-elongation         Kuwahara *et al.* \[[@bib51]\]
                            Splice-site \[[@bib2]\]                                                                                                                                                             
  1       1                 IVS2-1G\>A                                                                                                                     NA       G-to-A              NA                      D. G. Bichet *et al.*, unpublished
  2       1                 IVS3+1G\>A                                                                                                                     NA       G-to-A              NA                      Marr *et al.* \[[@bib53]\]
  46      53                Note: a family was counted only once if the affected child was homozygous or if the affected child was compound heterozygous                                                        

![A representation of the AQP2 protein and identification of 46 putative disease-causing AQP2 mutations. A monomer is represented with six transmembrane helices. The location of the PKA phosphorylation site (Pa) is indicated. The extracellular, transmembrane and cytoplasmic domains are defined according to Deen *et al.* \[[@bib17]\]. Solid symbols indicate the location of the mutations (for references, view [Table 1](#tbl1){ref-type="table"}): M1I; L22V; V24A; L28P; G29S; A47V; Q57P; G64R; N68S; A70D; V71M; R85X; G100X; G100V; G100R; I107D; 369delC; T125M; T126M; A147T; D150E; V168M; G175R; G180S; C181W; P185A; R187C; R187H; A190T; G196D; W202C; G215C; S216P; S216F; K228E; R254Q; R254L; E258K and P262L. GenBank accession numbers---AQP2: AF147092, Exon 1; AF147093, Exons 2 through 4. NPA motifs and the *N*-glycosylation site are also indicated.](ndtplussfs029f03_4c){#fig3}

In patients with hereditary polyuria, an X-linked inheritance will suggest X-linked *AVPR2* mutations and autosomal-recessive cases will be in favor of *AQP2* mutations but we are recommending the sequencing analysis of *AVPR2* first and then *AQP2* genes in all patients. These genes are, with a few exceptions, relatively small and easy to sequence. This genomic information is key to the routine care of patients with congenital polyuria and, as in other genetic diseases, reduces health costs and provides psychological benefits to patients and their families: an example of the possibility to help families living at a distance from a referral center is given in [Figure 4](#fig4){ref-type="fig"}.

![A young patient\'s thirsty since birth.](ndtplussfs029f04_ht){#fig4}

Signaling of vasopressin and insertion of AQP2 water channels in the luminal membrane of principal cells of the collecting duct: the work of five Nobel Prize recipients
========================================================================================================================================================================

The transfer of water across the principal cells of the collecting ducts is now known at such a detailed level that billions of molecules of water traversing the membrane can be represented; see useful teaching tools at <http://www.mpibpc.gwdg.de/abteilungen/073/gallery.html> and <http://www.ks.uiuc.edu/research/aquaporins>. The 2003 Nobel Prize in chemistry was awarded to Peter Agre and Roderick MacKinnon, who solved two complementary problems presented by the cell membrane: how does a cell let one type of ion through the lipid membrane to the exclusion of other ions? And how does it permeate water without ions? This contributed to creating momentum and renewed interest in basic discoveries related to the transport of water and indirectly to diabetes insipidus \[[@bib57], [@bib58]\]. The first step in the action of AVP (Synthetized by du Vigneaud, Nobel Prize in Chemistry 1955) \[[@bib59]\] on water excretion is its binding to arginine vasopressin type 2 receptors (hereafter referred to as V2 receptors) on the basolateral membrane of the collecting duct cells ([Figure 5](#fig5){ref-type="fig"}). The human *AVPR2* gene that codes for the V2 receptor is located in the chromosome region Xq28 and has three exons and two small introns \[[@bib12], [@bib60]\]. The sequence of the complementary DNA predicts a polypeptide of 371 amino acids with seven transmembrane, four extracellular and four cytoplasmic domains. The activation of the V2 receptor on renal collecting tubules stimulates adenylyl cyclase via the stimulatory G protein (Gs) (1994 Nobel Prize in Physiology and Medicine to Rodbell and Gilman for signal transduction and G-proteins) and promotes the cAMP-mediated incorporation of water channels into the luminal surface of these cells \[[@bib61]\]. E. Sutherland and T. Rall isolated cAMP in 1956 and Sutherland was awarded the Nobel Prize in Physiology or Medicine in 1971 \[[@bib62]\]. There are two ubiquitously expressed intracellular cAMP receptors: (i) the classical protein kinase A (PKA) that is a cAMP-dependent protein kinase and (ii) the recently discovered exchange protein directly activated by cAMP that is a cAMP-regulated guanine nucleotide exchange factor. Both these receptors contain an evolutionally conserved cAMP-binding domain that acts as a molecular switch for sensing intracellular cAMP levels to control diverse biological functions \[[@bib63]\]. Several proteins participating in the control of cAMP-dependent AQP2 trafficking have been identified; for example, A-kinase-anchoring proteins tethering PKA to cellular compartments; phosphodiesterases regulating the local cAMP level; cytoskeletal components such as F-actin and microtubules; small GTPases of the Rho family controlling cytoskeletal dynamics; motor proteins transporting AQP2-bearing vesicles to and from the plasma membrane for exocytic insertion and endocytic retrieval and SNAREs inducing membrane fusions, hsc70, a chaperone important for endocytic retrieval. These processes are the molecular basis of the vasopressin-induced increase in the osmotic water permeability of the apical membrane of the collecting tubule \[[@bib64]--[@bib66]\].

![Schematic representation of the effect of vasopressin (AVP) to increase water permeability in the principal cells of the collecting duct. AVP is bound to the V~2~ receptor (a G-protein-linked receptor) on the basolateral membrane. The basic process of G-protein-coupled receptor signaling consists of three steps: a hepta-helical receptor that detects a ligand (in this case, AVP) in the extracellular milieu, a G-protein (G~α~ ~s~) that dissociates into a subunits bound to guanosine triphosphate and bg subunits after interaction with the ligand-bound receptor and an effector (in this case, adenylyl cyclase) that interacts with dissociated G-protein subunits to generate small molecule second messengers. AVP activates adenylyl cyclase, increasing the intracellular concentration of cAMP. The topology of adenylyl cyclase is characterized by two tandem repeats of six hydrophobic transmembrane domains separated by a large cytoplasmic loop and terminates in a large intracellular tail. The dimeric structure (C~1~ and C~2~) of the catalytic domains is represented. Conversion of adenosine triphosphate (ATP) to cAMP takes place at the dimer interface. Two aspartate residues (in C~1~) coordinate two metal co-factors (Mg^2+^ or Mn^2+^ represented here as two small black circles), which enable the catalytic function of the enzyme. Adenosine is shown as an open circle and the three phosphate groups (ATP) are shown as smaller open circles. PKA is the target of the generated cAMP. The binding of cAMP to the regulatory subunits of PKA induces a conformational change, causing these subunits to dissociate from the catalytic subunits. These activated subunits (C) as shown here are anchored to an aquaporin-2 (AQP2)-containing endocytic vesicle via an A-kinase-anchoring protein. The local concentration and distribution of the cAMP gradient are limited by phosphodiesterases (PDEs). Cytoplasmic vesicles carrying the water channels (represented as homotetrameric complexes) are fused to the luminal membrane in response to AVP, thereby increasing the water permeability of this membrane. The dissociation of the A-kinase-anchoring protein from the endocytic vesicle is not represented. Microtubules and actin filaments are necessary for vesicle movement toward the membrane. When AVP is not available, AQP2 water channels are retrieved by an endocytic process, and water permeability returns to its original low rate. Aquaporin-3 (AQP3) and aquaporin-4 (AQP4) water channels are expressed constitutively at the basolateral membrane.](ndtplussfs029f05_4c){#fig5}

How could we decrease urine flow in patients bearing AQP2 mutations?
====================================================================

The actions of vasopressin in the distal nephron are possibly modulated by prostaglandin E2, nitric oxide \[[@bib67]\] and by luminal calcium concentration. PGE2 is synthesized and released in the collecting duct, which expresses all four E-prostanoid receptors (EP1--4). Both EP2 and EP4 can signal via increased cAMP. Olesen *et al.* \[[@bib68]\] hypothesized that selective EP receptor stimulation could mimic the effects of vasopressin and demonstrated that, at physiological levels, PGE2 markedly increased apical membrane abundance and phosphorylation of AQP2 *in vitro* and *ex vivo*, leading to increased cell water permeability. In their experiments, both EP2- and EP4-selective agonists were able to mimic these effects. Furthermore, an EP2 agonist was able to positively regulate urinary-concentrating mechanisms in an animal model of NDI where AVPR2 receptors were blocked by Tolvaptan, a non-peptide V2 antagonist. These results reveal an alternative mechanism for regulating water transport in the collecting duct that have major importance for understanding whole-body water homeostasis and provide a rationale for investigations into EP receptor agonist use in X-linked NDI treatment.

In patients with *AQP2* mutations, bypassing the vasopressin V2 receptor will not be of any therapeutic value; therefore, the classical decrease in osmotic load described by Orloff and Earley \[[@bib69]\], well before any molecular identification of the genes responsible for hereditary NDI, should be used. When the urine osmolality is fixed, as in nephrogenic DI, the urine output is determined by solute excretion. Suppose that the maximum urine osmolality is 150 mosmol/kg. In this setting, the daily urine volume will be 5 L if solute excretion is in the normal range at 750 mosmol/day, but only 3 L if solute excretion is lowered to 450 mosmol/day by dietary modification.

These observations provide the rationale for the use of a low-salt low-protein diet to diminish the urine output in NDI. The reduction in urine output will be directly proportional to the decrease in solute intake and excretion. Restriction of salt intake to ≤100 mEq/day (2.3 g sodium) and protein intake to ≤1.0 g/kg may be reasonable goals, but such diets are not easy to achieve and maintain. Furthermore, protein restriction in infants and young children may be harmful and is not advised. A thiazide diuretic (such as hydrochlorothiazide, 25 mg once or twice daily) acts by inducing mild volume depletion. As little as a 1--1.5 kg weight loss in adults with hereditary, NDI can reduce the urine output by \>50% \[e.g. from 10 to \<3.5 L/day in a study of patients with NDI on a severely sodium-restricted diet (9 mEq/day)\] \[[@bib69], [@bib70]\].
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